Ex vivo enrichment of circulating anti-Tumor T cells from both cutaneous and ocular melanoma patients: Clinical implications for adoptive cell transfer therapy

Tonia Mazzarella, Valeria Cambiaghi, Nathalie Rizzo, Lorenzo Pilla, Danilo Parolini, Elena Orsenigo, Annalisa Colucci, Giulio Modorati, Claudio Doglioni, Giorgio Parmiani, Cristina Maccalli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Tumor-inWltrating lymphocytes (TILs) have been successfully used for adoptive cell transfer (ACT) immunotherapy; however, due to their scarce availability, this therapy is possible for a limited fraction of cutaneous melanoma patients. We assessed whether an eVective protocol for ex vivo T-cell expansion from peripheral blood mononuclear cells (PBMCs), suitable for ACT of both cutaneous and ocular melanoma patients, could be identi- Wed. PBMCs from both cutaneous and ocular melanoma patients were stimulated in vitro with autologous, irradiated melanoma cells (mixed lymphocyte tumor cell culture; MLTCs) in the presence of IL-2 and IL-15 followed by the rapid expansion protocol (REP). The functional activity of these T lymphocytes was characterized and compared with that of TILs. In addition, the immune inWltration in vivo of ocular melanoma lesions was analyzed. An eYcient in vitro MLTC expansion of melanoma reactive T cells was achieved from all PBMC's samples obtained in 7 cutaneous and ocular metastatic melanoma patients. Large numbers of melanoma-speciWc T cells could be obtained when the REP protocol was applied to these MLTCs. Most MLTCs were enriched in non-Terminally diVerentiated TEM cells homogeneously expressing co-stimulatory molecules (e.g., NKG2D, CD28, CD134, CD137). A similar pattern of anti-Tumor activity, in association with a more variable expression of co-stimulatory molecules, was detected on short-Term in vitro cultured TILs isolated from the same patients. In these ocular melanoma patients, we observed an immune inWltrate with suppressive characteristics and a low rate of ex vivo growing TILs (28.5% of our cases). Our MLTC protocol overcomes this limitation, allowing the isolation of T lymphocytes with eVector functions even in these patients. Thus, anti-Tumor circulating PBMC-derived T cells could be eYciently isolated from melanoma patients by our novel ex vivo enrichment protocol. This protocol appears suitable for ACT studies of cutaneous and ocular melanoma patients.

Original languageEnglish
Pages (from-to)1169-1182
Number of pages14
JournalCancer Immunology, Immunotherapy
Volume61
Issue number8
DOIs
Publication statusPublished - Aug 2012
Externally publishedYes

Fingerprint

Adoptive Transfer
Cell- and Tissue-Based Therapy
Melanoma
T-Lymphocytes
Skin
Neoplasms
Lymphocytes
Blood Cells
Thomsen-Friedenreich antibodies
Interleukin-15
Immunotherapy
Interleukin-2
Cell Culture Techniques

Keywords

  • Cutaneous melanoma
  • Immunotherapy
  • Ocular melanoma
  • T-cell responses

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Ex vivo enrichment of circulating anti-Tumor T cells from both cutaneous and ocular melanoma patients : Clinical implications for adoptive cell transfer therapy. / Mazzarella, Tonia; Cambiaghi, Valeria; Rizzo, Nathalie; Pilla, Lorenzo; Parolini, Danilo; Orsenigo, Elena; Colucci, Annalisa; Modorati, Giulio; Doglioni, Claudio; Parmiani, Giorgio; Maccalli, Cristina.

In: Cancer Immunology, Immunotherapy, Vol. 61, No. 8, 08.2012, p. 1169-1182.

Research output: Contribution to journalArticle

Mazzarella, T, Cambiaghi, V, Rizzo, N, Pilla, L, Parolini, D, Orsenigo, E, Colucci, A, Modorati, G, Doglioni, C, Parmiani, G & Maccalli, C 2012, 'Ex vivo enrichment of circulating anti-Tumor T cells from both cutaneous and ocular melanoma patients: Clinical implications for adoptive cell transfer therapy', Cancer Immunology, Immunotherapy, vol. 61, no. 8, pp. 1169-1182. https://doi.org/10.1007/s00262-011-1179-z
Mazzarella, Tonia ; Cambiaghi, Valeria ; Rizzo, Nathalie ; Pilla, Lorenzo ; Parolini, Danilo ; Orsenigo, Elena ; Colucci, Annalisa ; Modorati, Giulio ; Doglioni, Claudio ; Parmiani, Giorgio ; Maccalli, Cristina. / Ex vivo enrichment of circulating anti-Tumor T cells from both cutaneous and ocular melanoma patients : Clinical implications for adoptive cell transfer therapy. In: Cancer Immunology, Immunotherapy. 2012 ; Vol. 61, No. 8. pp. 1169-1182.
@article{461eaf9b50034eaa8c38137c6bdab78a,
title = "Ex vivo enrichment of circulating anti-Tumor T cells from both cutaneous and ocular melanoma patients: Clinical implications for adoptive cell transfer therapy",
abstract = "Tumor-inWltrating lymphocytes (TILs) have been successfully used for adoptive cell transfer (ACT) immunotherapy; however, due to their scarce availability, this therapy is possible for a limited fraction of cutaneous melanoma patients. We assessed whether an eVective protocol for ex vivo T-cell expansion from peripheral blood mononuclear cells (PBMCs), suitable for ACT of both cutaneous and ocular melanoma patients, could be identi- Wed. PBMCs from both cutaneous and ocular melanoma patients were stimulated in vitro with autologous, irradiated melanoma cells (mixed lymphocyte tumor cell culture; MLTCs) in the presence of IL-2 and IL-15 followed by the rapid expansion protocol (REP). The functional activity of these T lymphocytes was characterized and compared with that of TILs. In addition, the immune inWltration in vivo of ocular melanoma lesions was analyzed. An eYcient in vitro MLTC expansion of melanoma reactive T cells was achieved from all PBMC's samples obtained in 7 cutaneous and ocular metastatic melanoma patients. Large numbers of melanoma-speciWc T cells could be obtained when the REP protocol was applied to these MLTCs. Most MLTCs were enriched in non-Terminally diVerentiated TEM cells homogeneously expressing co-stimulatory molecules (e.g., NKG2D, CD28, CD134, CD137). A similar pattern of anti-Tumor activity, in association with a more variable expression of co-stimulatory molecules, was detected on short-Term in vitro cultured TILs isolated from the same patients. In these ocular melanoma patients, we observed an immune inWltrate with suppressive characteristics and a low rate of ex vivo growing TILs (28.5{\%} of our cases). Our MLTC protocol overcomes this limitation, allowing the isolation of T lymphocytes with eVector functions even in these patients. Thus, anti-Tumor circulating PBMC-derived T cells could be eYciently isolated from melanoma patients by our novel ex vivo enrichment protocol. This protocol appears suitable for ACT studies of cutaneous and ocular melanoma patients.",
keywords = "Cutaneous melanoma, Immunotherapy, Ocular melanoma, T-cell responses",
author = "Tonia Mazzarella and Valeria Cambiaghi and Nathalie Rizzo and Lorenzo Pilla and Danilo Parolini and Elena Orsenigo and Annalisa Colucci and Giulio Modorati and Claudio Doglioni and Giorgio Parmiani and Cristina Maccalli",
year = "2012",
month = "8",
doi = "10.1007/s00262-011-1179-z",
language = "English",
volume = "61",
pages = "1169--1182",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "8",

}

TY - JOUR

T1 - Ex vivo enrichment of circulating anti-Tumor T cells from both cutaneous and ocular melanoma patients

T2 - Clinical implications for adoptive cell transfer therapy

AU - Mazzarella, Tonia

AU - Cambiaghi, Valeria

AU - Rizzo, Nathalie

AU - Pilla, Lorenzo

AU - Parolini, Danilo

AU - Orsenigo, Elena

AU - Colucci, Annalisa

AU - Modorati, Giulio

AU - Doglioni, Claudio

AU - Parmiani, Giorgio

AU - Maccalli, Cristina

PY - 2012/8

Y1 - 2012/8

N2 - Tumor-inWltrating lymphocytes (TILs) have been successfully used for adoptive cell transfer (ACT) immunotherapy; however, due to their scarce availability, this therapy is possible for a limited fraction of cutaneous melanoma patients. We assessed whether an eVective protocol for ex vivo T-cell expansion from peripheral blood mononuclear cells (PBMCs), suitable for ACT of both cutaneous and ocular melanoma patients, could be identi- Wed. PBMCs from both cutaneous and ocular melanoma patients were stimulated in vitro with autologous, irradiated melanoma cells (mixed lymphocyte tumor cell culture; MLTCs) in the presence of IL-2 and IL-15 followed by the rapid expansion protocol (REP). The functional activity of these T lymphocytes was characterized and compared with that of TILs. In addition, the immune inWltration in vivo of ocular melanoma lesions was analyzed. An eYcient in vitro MLTC expansion of melanoma reactive T cells was achieved from all PBMC's samples obtained in 7 cutaneous and ocular metastatic melanoma patients. Large numbers of melanoma-speciWc T cells could be obtained when the REP protocol was applied to these MLTCs. Most MLTCs were enriched in non-Terminally diVerentiated TEM cells homogeneously expressing co-stimulatory molecules (e.g., NKG2D, CD28, CD134, CD137). A similar pattern of anti-Tumor activity, in association with a more variable expression of co-stimulatory molecules, was detected on short-Term in vitro cultured TILs isolated from the same patients. In these ocular melanoma patients, we observed an immune inWltrate with suppressive characteristics and a low rate of ex vivo growing TILs (28.5% of our cases). Our MLTC protocol overcomes this limitation, allowing the isolation of T lymphocytes with eVector functions even in these patients. Thus, anti-Tumor circulating PBMC-derived T cells could be eYciently isolated from melanoma patients by our novel ex vivo enrichment protocol. This protocol appears suitable for ACT studies of cutaneous and ocular melanoma patients.

AB - Tumor-inWltrating lymphocytes (TILs) have been successfully used for adoptive cell transfer (ACT) immunotherapy; however, due to their scarce availability, this therapy is possible for a limited fraction of cutaneous melanoma patients. We assessed whether an eVective protocol for ex vivo T-cell expansion from peripheral blood mononuclear cells (PBMCs), suitable for ACT of both cutaneous and ocular melanoma patients, could be identi- Wed. PBMCs from both cutaneous and ocular melanoma patients were stimulated in vitro with autologous, irradiated melanoma cells (mixed lymphocyte tumor cell culture; MLTCs) in the presence of IL-2 and IL-15 followed by the rapid expansion protocol (REP). The functional activity of these T lymphocytes was characterized and compared with that of TILs. In addition, the immune inWltration in vivo of ocular melanoma lesions was analyzed. An eYcient in vitro MLTC expansion of melanoma reactive T cells was achieved from all PBMC's samples obtained in 7 cutaneous and ocular metastatic melanoma patients. Large numbers of melanoma-speciWc T cells could be obtained when the REP protocol was applied to these MLTCs. Most MLTCs were enriched in non-Terminally diVerentiated TEM cells homogeneously expressing co-stimulatory molecules (e.g., NKG2D, CD28, CD134, CD137). A similar pattern of anti-Tumor activity, in association with a more variable expression of co-stimulatory molecules, was detected on short-Term in vitro cultured TILs isolated from the same patients. In these ocular melanoma patients, we observed an immune inWltrate with suppressive characteristics and a low rate of ex vivo growing TILs (28.5% of our cases). Our MLTC protocol overcomes this limitation, allowing the isolation of T lymphocytes with eVector functions even in these patients. Thus, anti-Tumor circulating PBMC-derived T cells could be eYciently isolated from melanoma patients by our novel ex vivo enrichment protocol. This protocol appears suitable for ACT studies of cutaneous and ocular melanoma patients.

KW - Cutaneous melanoma

KW - Immunotherapy

KW - Ocular melanoma

KW - T-cell responses

UR - http://www.scopus.com/inward/record.url?scp=84865708322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865708322&partnerID=8YFLogxK

U2 - 10.1007/s00262-011-1179-z

DO - 10.1007/s00262-011-1179-z

M3 - Article

C2 - 22207316

AN - SCOPUS:84865708322

VL - 61

SP - 1169

EP - 1182

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 8

ER -